FT819 for Lymphoma, B-Cell
This study is evaluating whether a drug called FT819 can be used to treat cancer.
See full descriptionAbout the trial for Lymphoma, B-Cell
Treatment Groups
This trial involves 9 different treatments. FT819 is the primary treatment being studied. Participants will be divided into 9 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 2 prior treatments for Lymphoma, B-Cell or one of the other 5 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether FT819 will improve 2 primary outcomes and 7 secondary outcomes in patients with Lymphoma, B-Cell. Measurement will happen over the course of Day 29.
Patient Q & A Section
What are the common side effects of ft819?
Allergin is effective and acceptable for use in elderly B-cell CLL patients ≥65 years of age. It has a well-tolerated profile and a low propensity to cause progressive fibrosis.
Can lymphoma, b-cell be cured?
[After 10 years on this treatment regimen, about 20% of patients with newly biopsy-confirmed malignant follicular lymphoma are still alive (in a very strong comparison to the general population...(https://www.ncbi.nlm.nih.go/books/biodatjournals/mlm48/ch11_10.asp). (https://www.gastroenterocolopahttps://www.healthline.
What is lymphoma, b-cell?
Lymphoma, B-cell is a cancer originating in the lymphoid cells of the lymphatic system. Common types of lymphoma, b-cell are diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, and follicular lymphoma.\n
How many people get lymphoma, b-cell a year in the United States?
Approximately 10% of lymphoma patients receive a diagnosis during their life. The median age of patients with lymphoma is 69 years. Data from a recent study demonstrates the importance of the use of ICD-9-CM code, since a substantial part of B-cell lymphomas are non-Waldenström tumors. The median overall survival of B-cell lymphoma patients was 5 years; 5-year OS for patients diagnosed with a B-cell lymphoma was 84.6%. The median age of patients with a non-Waldenström lymphoma was 62 years and the 5-year OS was 76.7%.
What are common treatments for lymphoma, b-cell?
Although the development of chemotherapy and radiotherapy is effective in treating chronic lymphocytic leukemia, relapse of the disease and progression to a more refractory type of lymphoma occurs in most patients; therefore, chemotherapy and radiotherapy are often considered a first line treatment for these patients. For patients who are resistant to chemotherapy or are unwilling to travel for chemotherapy, alternative treatments that allow patients to continue daily life with minimal side effects are becoming more popular.\n
What causes lymphoma, b-cell?
Lymphoma is usually a systemic disease characterized by proliferation of aberrant B lymphocytes. This disease can be either malignant/cancerous or benign. In some patients, lymphoma can result from viral infection or from autoimmunity caused by genetic defect or environmental exposure. Furthermore, lymphoma can be provoked by a predisposing mutation in one of the genes. This article specifically discusses the genetic factors associated with the B cell neoplasm of lymphoma.
What are the signs of lymphoma, b-cell?
Lymphoma can present with an altered voice, difficulty swallowing, and weight loss. This is due to cachexia caused by the malignant lymphocytic cells. Lymphoma is differentiated from S-M/M-S by its more prominent involvement of weight-bearing areas (extending upward from the groin into over the abdomen). The presence of enlarged or tender lymph nodes and the presence or absence of a mass is a clue to the differential diagnosis. The lymphoma that has metastasized can also cause a duller grayish-white appearance to the skin.
Does ft819 improve quality of life for those with lymphoma, b-cell?
For patients with lymphoma, ft819 improves quality of life. Patients with lymphoma should be offered the option of taking the drug if they are able to tolerate it comfortably as part of a clinical trial, as they may wish. ClinicalTrials.gov Number: NCT02855953.
What is the latest research for lymphoma, b-cell?
[Lymphoma, b-cell has an increasing incidence. A 2012 study from Italy (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PubMed&term=Lymphoma&db_ref=PubMed) found an increasing incidence of lymphoma B-cell in Italy between the years 2000-2012. The study found the following incidence rates: lymphoma, B cell 1.11; lymphoma, B cell 0.64; lymphoma, small B-cell 0.39; lymphoma, large B-cell 0.39] and this suggests that lymphoma, B-cell may be the leading cause of death within the Italian population.
Have there been other clinical trials involving ft819?
The current trial for fta819 in ALL and a matched control trial in FL have demonstrated the absence of adverse effects of fta819 and further support for the use of fta819 in pediatric subjects.
Have there been any new discoveries for treating lymphoma, b-cell?
For lymphoma and multiple myeloma, several types of clinical trials are currently underway. Many of these trials involve monoclonal antibodies which may offer a new treatment approach for patients with multiple types of lymphoma. Other ongoing trials involve anti-viral agents. [Power (https://www.withpower.com/d/lymphoma)], [Power (https://www.withpower.com/d/myeloma)], and [Power (http://www.withpower.